Sugi Predict

Sugi Predict / Targets / WEE1

WEE1

Wee1-like protein kinase · P30291 · WEE1 on Sugi Atlas →

48,725 patent compounds predicted against WEE1, 32,356 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL214495 SCHEMBL214495 0.53 17/20
SCHEMBL216617 SCHEMBL216617 0.53 17/20
SCHEMBL215881 SCHEMBL215881 0.54 16/20
SCHEMBL215852 SCHEMBL215852 0.56 15/20
SCHEMBL216546 SCHEMBL216546 0.55 15/20
SCHEMBL189352 SCHEMBL189352 0.52 15/20
SCHEMBL214278 SCHEMBL214278 0.51 15/20
SCHEMBL219529 SCHEMBL219529 0.56 14/20
SCHEMBL217692 SCHEMBL217692 0.51 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL218585) 0.51 14/20
SCHEMBL214363 SCHEMBL214363 0.50 14/20
SCHEMBL217029 SCHEMBL217029 0.58 13/20
SCHEMBL215998 SCHEMBL215998 0.55 12/20
SCHEMBL214554 SCHEMBL214554 0.53 12/20
SCHEMBL1115541 SCHEMBL1115541 0.52 9/20
SCHEMBL1115328 SCHEMBL1115328 0.52 8/20
SCHEMBL868129 SCHEMBL868129 0.75 5/20
SCHEMBL374566 SCHEMBL374566 0.52 5/20
SCHEMBL1116423 SCHEMBL1116423 0.51 5/20
SCHEMBL1115542 SCHEMBL1115542 0.48 5/20

Clinical trials — most relevant to WEE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer PHASE2COMPLETED
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas PHASE1/PHASE2COMPLETED
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma PHASE2ACTIVE_NOT_RECRUITING
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer PHASE1/PHASE2UNKNOWN
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency PHASE2COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. PHASE2ACTIVE_NOT_RECRUITING
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment PHASE2NOT_YET_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Study of SGR-3515 In Participants With Advanced Solid Tumors. PHASE1RECRUITING
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial PHASE1RECRUITING
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer PHASE1RECRUITING
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer EARLY_PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
The Screening Protocol for The VIKTORY Trial nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer nanACTIVE_NOT_RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a WEE1 binder may also engage these)

ProteinNameSimilarity
Q63802 — 1.000 Q63802 →
P47810 — 1.000 P47810 →
Q8AYK6 — 0.993 Q8AYK6 →
Q8QGV2 — 0.989 Q8QGV2 →
A4QNA8 — 0.976 A4QNA8 →
Q9WU40 — 0.976 Q9WU40 →
Q4R4I0 — 0.975 Q4R4I0 →
TERF2IP Telomeric repeat-binding factor 2-interacting protein 1 0.974 landscape →
Q6ZWB6 — 0.973 Q6ZWB6 →
Q62925 — 0.973 Q62925 →
Q6DFE0 — 0.973 Q6DFE0 →
Q50H33 — 0.972 Q50H33 →
D2HHP1 — 0.972 D2HHP1 →
Q99MU3 — 0.972 Q99MU3 →
P53349 — 0.972 P53349 →
Q9Y2U8 — 0.971 Q9Y2U8 →
P34908 — 0.971 P34908 →
P12755 — 0.971 P12755 →
Q80Z30 — 0.971 Q80Z30 →
Q5SUE8 — 0.971 Q5SUE8 →
Q8K4J0 — 0.971 Q8K4J0 →
P0C6S7 — 0.971 P0C6S7 →
Q496Y0 — 0.971 Q496Y0 →
A4FV61 — 0.970 A4FV61 →
BCR Breakpoint cluster region protein 0.970 landscape →
STK35 Serine/threonine-protein kinase 35 0.970 landscape →
Q8K2W6 — 0.970 Q8K2W6 →
Q8WY91 — 0.970 Q8WY91 →
Q5QP82 — 0.970 Q5QP82 →
P49797 — 0.970 P49797 →